Last $4.40 USD
Change Today +0.04 / 0.92%
Volume 117.3K
TRGT On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

targacept inc (TRGT) Snapshot

Open
$4.40
Previous Close
$4.36
Day High
$4.50
Day Low
$4.38
52 Week High
12/16/13 - $6.11
52 Week Low
05/20/14 - $3.52
Market Cap
148.7M
Average Volume 10 Days
472.3K
EPS TTM
$-1.48
Shares Outstanding
33.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TARGACEPT INC (TRGT)

Related News

No related news articles were found.

targacept inc (TRGT) Related Businessweek News

No Related Businessweek News Found

targacept inc (TRGT) Details

Targacept, Inc., a biopharmaceutical company, is engaged in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates in Phase IIb clinical trials include TC-5214 to treat overactive bladder; TC-1734 for the treatment of mild to moderate Alzheimer’s disease; and TC-5619 for the treatment of negative symptoms and cognitive dysfunction in schizophrenia. The company’s product candidates also comprise TC-6499 for the treatment for gastrointestinal disorders; TC-6987, a novel small molecule that modulates the activity of the a7 NNR; and AZD1446, a novel small molecule that modulates the activity of the a4ß2 NNR. It has a collaboration agreement with AstraZeneca AB to develop AZD1446 and earlier-stage compounds. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.

39 Employees
Last Reported Date: 03/14/14
Founded in 1997

targacept inc (TRGT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $687.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $500.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $140.7K
Vice President of Clinical Development and Re...
Total Annual Compensation: $397.0K
Compensation as of Fiscal Year 2013.

targacept inc (TRGT) Key Developments

Targacept, Inc.(NasdaqGS:TRGT) dropped from Russell 2000 Index

Targacept, Inc. will be removed from the Russell 2000 Index.

Targacept, Inc.(NasdaqGS:TRGT) dropped from Russell 3000 Index

Targacept, Inc. will be removed from the Russell 3000 Index.

Targacept, Inc. Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis

Targacept, Inc. announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. TC-6499 is a novel small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNRs). The alpha3beta4 NNR is located throughout the gastrointestinal tract and, when modulated, is believed to increase cholinergic tone, which in turn leads to increased motility. Evidence from Phase 1 clinical trials suggest that TC-6499 may increase gastric motility. In addition, in a Phase 2a clinical trial involving 24 subjects, TC-6499 outperformed placebo on an objective secondary efficacy outcome measure, the number of spontaneous bowel movements per week, but not on the primary efficacy outcome measure of global symptom relief. The Phase 1/2 exploratory study is a double blind, placebo controlled, randomized, four-way crossover study planned to be conducted at sites in the United States. At least 18 subjects with diabetic gastroparesis will be required to complete the study and will receive one of four treatments (2 mg, 5 mg and 10 mg of TC-6499 and placebo) in a randomized, crossover manner on each of four treatment visits, with each dosing period separated by approximately seven days. The primary endpoint of the study is change in gastric emptying half-time (BT t(1/2)), as measured by a carbon ((13) C) labeled gastric emptying breath test, for each active treatment relative to placebo. The study will also assess the safety, tolerability and pharmacokinetics of TC-6499.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRGT:US $4.40 USD +0.04

TRGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.33 CAD +0.005
Eli Lilly & Co $62.62 USD +0.16
Novartis AG SFr.80.00 CHF -0.30
Pfizer Inc $30.05 USD -0.10
View Industry Companies
 

Industry Analysis

TRGT

Industry Average

Valuation TRGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 817.4x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 273.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARGACEPT INC, please visit www.targacept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.